Why the study?
Does cilazapril reduce blood pressure and how do its pharmacokinetics differ in hypertensive patients with normal versus impaired renal function?
Does cilazapril reduce blood pressure and how do its pharmacokinetics differ in hypertensive patients with normal versus impaired renal function?
Cilazapril is an effective antihypertensive agent, but its dose should be reduced in patients with severe renal impairment due to delayed recovery of ACE activity and higher plasma concentrations of its active diacid.
Answers are grounded in this paper and cite their sources.
Supports cilazapril BP reduction without tachycardia and higher metabolite levels in renal impairment; leaves open dose optimization pending randomized trials.
A 1.25 mg dose of cilazapril, a new angiotensin-converting enzyme (ACE) inhibitor, was administered orally to two groups of hypertensive patients, five with normal renal function (NRF) and seven with impaired renal function (IRF), once daily for 5 or 8 consecutive days. Blood pressure, heart rate and serum ACE activity were measured up to 24 h following the initial and the last dose. Plasma level profiles of cilazapril and its active diacid were also evaluated on the first and the last day of treatment. 2. Cilazapril induced significant falls in both systolic and diastolic blood pressures without increasing heart rate. The antihypertensive effect was evident within 1 h after drug administration and was sustained for up to 24 h, particularly after consecutive dosing. 3. Serum ACE activity was markedly suppressed over 24 h. The recovery of ACE activity was delayed in the IRF group when compared with the NRF group. 4. Plasma concentrations of the active diacid in the IRF group were higher than in the NRF group with significant differences in the peak concentrations and area under the plasma concentration-time curve (AUC). The plasma concentration profile for the parent drug was similar for both the NRF and IRF groups. 5. A significant inverse correlation was found between the creatinine clearance and the AUC for the diacid. 6. Cilazapril is a potent ACE inhibitor with a prolonged duration of antihypertensive effect and is a useful agent for controlling blood pressure in hypertensives either with NRF or IRF. In patients with severe renal impairment the dose of cilazapril should be reduced.
No takes yet. Share an insight, caveat, or question.
Shionoiri et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: